N/A N=585 An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
Eyelash Hypotrichosis
Primary: Percentage of Subjects Satisfied With Latisse® — 92.48 Percentage of Subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=464 Bimatoprost in the Treatment of Eyelash Hypotrichosis
Idiopathic Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA) — 82.4…
Phase 3 N=357 Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Eyebrow Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale — 83.9; 77.1; 43.0 percentage of…
Phase 3 N=368 Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin
Hypotrichosis
Primary: Percentage of Treatment Responders at Month 4 — 39.3; 10.9 Percentage of Subjects
Phase 4 N=71 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
Eyelash Hypotrichosis · Alopecia Areata
Primary: Percentage of Participants With Adverse Events — 35.4; 43.5 Percentage of participants
Phase 4 N=89 Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
Hypotrichosis
Primary: Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4 — 69.6; 48.8 Percentage of Patients
N/A N=179 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women
Health
Primary: Eyelash Length as Measured by Digital Image Analysis (DIA) — 7.33 Millimeters (mm)
Phase 3 N=173 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 77.3; 17.6 Percentage of…
Phase 3 N=36 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 88.9; 27.8 Percentage of…
Phase 2 N=104 Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence
Eyelash Hypotrichosis
Primary: Change From Baseline in Eyelash Length at Month 3 — 5.65; 5.68; 5.95; 0.74 millimeters (mm)
Phase 3 N=278 Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence
Eyelashes
Primary: Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16 — 5.1; 2.1; 14.6; 7.8…
Phase 2 N=1 Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Clinician's Eyebrow Assessment — 0 score on a scale
Phase 2 N=33 LEV102 Topical Gel in Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
N/A N=21 Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Hypertrichosis
Primary: Efficacy of Bimatoprost in Lengthening of Eyelashes — 2; 1.1 mm
Phase 4 N=88 Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
Hypotrichosis
Primary: Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall — 67.4; 7.1 Percentage of participants
Phase 2 N=9 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
Male Pattern Hair Loss · Androgenetic Alopecia
Primary: Percent Change in Target Area Total Hair Count — -2.6; 27.4; 4.9; -5.8 percentage change in total hair count
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Phase 2 N=46 Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Blepharoptosis
Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen
Phase 2 N=48 ET-01 in Subjects With Lateral Canthal Lines
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
Phase 2 N=38 ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Lateral Canthal Lines, LCL · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…
Phase 4 N=62 Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
Eyelash Hypotrichosis
Primary: Change From Baseline in Eyelash Length at Week 20 — 5.92; 1.10 Millimeter (mm)
N/A N=14 Intense Pulsed Light Study for Dry Eye Disease
Dry Eyes Chronic
Primary: Tear Breakup Time Average — 3.3; 3.0; 4.1; 4.5 Seconds — p=0.3
Phase 2 N=79 ET-01 in Subjects With Lateral Canthal Lines, LCL-207
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 4; 1; 3…
Phase 2 N=75 ET-01 in Subjects With Lateral Canthal Lines, LCL-208
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 2; 0; 1…
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
Phase 2 N=31 LEO 124249 Ointment in the Treatment of Alopecia Areata
Alopecia Areata
Primary: Change in Severity of Alopecia Areata Tool (SALT) Score — -3.8; -3.4 units on a scale — p=0.97
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
Phase 2 N=306 Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
Alopecia · Baldness
Primary: Change From Baseline in Target Area Hair Count (TAHC) — 153.1; 161.1; 145.2; 163.0 terminal hairs/cm^2
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds